The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study
SBRT is a potent, minimally invasive option for managing pulmonary oligometastases, especially when preceded by immunotherapy. The 60 Gy in 10 fractions regimen demonstrated significant efficacy in terms of OS and LC, while maintaining manageable toxicity. Although the retrospective nature of the study introduces some selection bias, this dose regimen appears to offer a promising therapeutic option for pulmonary oligometastases. Further validation through well-designed prospective studies would help confirm the optimal SBRT dose and clarify the role of immunotherapy in this setting.
Authors
- Xiajing Qian (ORCID: https://orcid.org/0000-0001-8379-3226)
- Robert A. Ramirez (ORCID: https://orcid.org/0000-0001-8762-5852)
- Salma K. Jabbour (ORCID: https://orcid.org/0000-0001-8200-5371)
- Josephine Chou (ORCID: https://orcid.org/0000-0003-3202-7438)
- Yi Lü (ORCID: https://orcid.org/0000-0002-9722-569X)
- Yunyun Lu (ORCID: https://orcid.org/0009-0009-2095-389X)
- Wei Jiang (ORCID: https://orcid.org/0009-0008-8640-2882)
- Zhengxuying Fang
Institutions
- Rutgers, The State University of New Jersey (US)
- Ningbo University (CN)
- Johnson University (US)
- Ningbo Medical Center Lihuili Hospital (CN)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/jtd-24-1624
- Primary Topic
- Medical Imaging and Pathology Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Ningbo